| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b01401ec4dfda8e46c444f4b6702084 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5153 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-551
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6937
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6935 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-17 |
| filingDate |
2014-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e02b0087a3115b57b2b0b41ae4591517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8676e19b5316d1b42c1cd85be7c689f8 |
| publicationDate |
2015-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2015209284-A1 |
| titleOfInvention |
Dual-targeting drug carrier and method for fabricating the same |
| abstract |
The present invention discloses a dual-targeting drug carrier and a method for fabricating the same, wherein WGA- and FA-modified MPEG-PLA nanoparticles of the carrier enable the anticancer drugs encapsulated thereinside to pass through BBB and target human glioblastoma cells. The dual-target drug carrier is fabricated in an emulsion-solvent evaporation technology and verified with an in-vitro BBB model formed of HBMECs, HAs and HBVPs. The present invention can increase the permeability of the in-vitro BBB model to the dual-target drug carrier and promote the glioblastoma-inhibition effect. Therefore, the present invention would contribute to the clinical therapy of brain cancers substantially in the future. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108379590-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108404823-A |
| priorityDate |
2014-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |